HIV TREATMENT PROTOCOL WITH PEG-INTRON: STUDY SUB-STUDY P00737 AND STUDY P00738

Not Applicable

• Conditions: -B24 Unspecified human immunodeficiency virus [HIV] disease; Unspecified human immunodeficiency virus [HIV] disease; B24

• Registration Number: PER-017-03
• Lead Sponsor: SCHERING PLOUGH DEL PERU S.A.,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2003-03-11
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Subjects must receive a HAART regimen at present.
The following laboratory parameters must be met:
Platelet count> 75,000/mm3
Hemoglobin> 9 gm / dl
Absolute neutrophil count> 1,000/mm3
Creatinine <1.5 times the upper limit of normal
SGOT / SGPT <5 times the normal upper limit

Exclusion Criteria

People who are participating in clinical studies of drugs currently in research, or have done so in the previous month.
Subjects with a history of hypersensitivity to interferons.
Subjects with a history of moderate or severe depression, dementia, or other major psychiatric conditions that require medical treatment.

Study & Design

• Study Type: Interventional
• Study Design: Not specified